Seeking Alpha

Bristol-Myers Squibb (BMY) says it's stopped development of an experimental hepatitis C...

Bristol-Myers Squibb (BMY) says it's stopped development of an experimental hepatitis C treatment connected to the hospitalization of nine patients and the death of one. The drug, known as BMS-986094, had been used in a mid-stage clinical study, which BMY recently suspended. The cause of the adverse events, while not "definitively established," involved heart and kidney toxicity, the drug maker said.
Comments (4)
  • Why are you beating this issue to death. Let it go the company is a great company. The issue is weeks ago and your still talking about it. Old news that scares people. It is wrong and we all should be looking forward to the great things ahead for BMY. Fair disclosue I own the stock before this issue came up and still own it now and plan to buy more. It is a winner all the way.
    23 Aug 2012, 07:36 PM Reply Like
  • I think the notice says the development is stopped, previously reported it was suspended. Shares were up today in a really crummy market. I think it is a good company too.
    23 Aug 2012, 07:50 PM Reply Like
  • One of many in the pipeline. The stock has many other areas in the health field. Diabetes, cancer, blood thinners etc. One small blip that was blown way out of proportion.
    23 Aug 2012, 10:51 PM Reply Like
  • BMY's daclatasvir (formerly BMS-790052) combined with GILD's GS-7977 CURED 100% of genotype 1 and 91% of genotype 2/3 w/o interferon or ribavirin in phase II trials. This development was stopped by GILD and millions with HCV are now left to continue suffering and dying when what appears to be the best development in the history of HCV has been found. This is what all the news should be about!
    24 Aug 2012, 01:10 AM Reply Like
DJIA (DIA) S&P 500 (SPY)